1
|
Rossi JF, Céballos P, Lu ZY. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond) 2019; 39:34. [PMID: 31200766 PMCID: PMC6567551 DOI: 10.1186/s40880-019-0379-3] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 06/03/2019] [Indexed: 02/06/2023] Open
Abstract
Cancer cell growth is associated with immune surveillance failure. Nowadays, restoring the desired immune response against cancer cells remains a major therapeutic strategy. Due to the recent advances in biological knowledge, efficient therapeutic tools have been developed to support the best bio-clinical approaches for immune precision therapy. One of the most important successes in immune therapy is represented by the applicational use of monoclonal antibodies, particularly the use of rituximab for B-cell lymphoproliferative disorders. More recently, other monoclonal antibodies have been developed, to inhibit immune checkpoints within the tumor microenvironment that limit immune suppression, or to enhance some immune functions with immune adjuvants through different targets such as Toll-receptor agonists. The aim is to inhibit cancer proliferation by the diminishing/elimination of cancer residual cells and clinically improving the response duration with no or few adverse effects. This effect is supported by enhancing the number, functions, and activity of the immune effector cells, including the natural killer (NK) lymphocytes, NKT-lymphocytes, γδ T-lymphocytes, cytotoxic T-lymphocytes, directly or indirectly through vaccines particularly with neoantigens, and by lowering the functions of the immune suppressive cells. Beyond these new therapeutics and their personalized usage, new considerations have to be taken into account, such as epigenetic regulation particularly from microbiota, evaluation of transversal functions, particularly cellular metabolism, and consideration to the clinical consequences at the body level. The aim of this review is to discuss some practical aspects of immune therapy, giving to clinicians the concept of immune effector cells balancing between control and tolerance. Immunological precision medicine is a combination of modern biological knowledge and clinical therapeutic decisions in a global vision of the patient.
Collapse
Affiliation(s)
- Jean-François Rossi
- Institut Sainte Catherine, 84918, Avignon, France. .,Université Montpellier 1, UFR Médecine, 34396, Montpellier, France. .,Département d'Hématologie, CHU de Montpellier, 34295, Montpellier, France.
| | - Patrice Céballos
- Département d'Hématologie, CHU de Montpellier, 34295, Montpellier, France
| | - Zhao-Yang Lu
- Unité de Thérapie Cellulaire, CHU Saint-Eloi, 34295, Montpellier, France
| |
Collapse
|
2
|
Inogés S, de Cerio ALD, Villanueva H, Soria E, Pastor F, Bendandi M. Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines 2014; 10:801-9. [DOI: 10.1586/erv.11.44] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
3
|
Villanueva H, de Cerio ALD, Inoges S, Pastor F, Soldevilla MM, Bendandi M. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Expert Rev Vaccines 2014; 10:1661-9. [DOI: 10.1586/erv.11.132] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
4
|
Inoges S, de Cerio ALD, Villanueva H, Pastor F, Soria E, Bendandi M. Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol 2011; 2:237-44. [PMID: 21773074 PMCID: PMC3139034 DOI: 10.5306/wjco.v2.i6.237] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2011] [Revised: 03/08/2011] [Accepted: 03/15/2011] [Indexed: 02/06/2023] Open
Abstract
Over the last two decades, lymphoma idiotype vaccines have been the first human cancer vaccines to show striking evidence of biological and clinical efficacy on the one hand, as well as clinical benefit on the other. More recently, however, three large-scale, independent, randomized clinical trials on idiotypic vaccination have failed to achieve their main clinical endpoints for reasons likely to depend more on flaws in each clinical trial’s study design than on each vaccination strategy per se. Independently of these considerations, a major hurdle for the development of this substantially innocuous and yet potentially very effective type of treatment has been the fact that, even to date, no factors ascertainable before vaccination have been prospectively singled out as predictors of subsequently vaccine-induced, idiotype-specific immune as well as clinical responses. The aim of this review article is precisely to analyze what has been and what could be done in this respect in order to give a greater chance of success to future trials aimed at regulatory approval of idiotype vaccines.
Collapse
Affiliation(s)
- Susana Inoges
- Susana Inoges, Ascension Lopez-Diaz de Cerio, Helena Villanueva, Fernando Pastor, Elena Soria, Maurizio Bendandi, Lab of Immunotherapy - Oncology Division, Center for Applied Medical Research, Avda Pio XII, 55, 31008 Pamplona (Navarra), Spain
| | | | | | | | | | | |
Collapse
|
5
|
Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait. Pharmaceuticals (Basel) 2010; 3:667-678. [PMID: 27713273 PMCID: PMC4033974 DOI: 10.3390/ph3030667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Revised: 03/03/2010] [Accepted: 03/08/2010] [Indexed: 11/22/2022] Open
Abstract
Hybridoma-derived idiotype vaccines have been used for the experimental treatment of human lymphoma over the last twenty years, providing evidence of biological efficacy, clinical efficacy and clinical benefit. However, the product that has come closer to regulatory approval is unlikely to clear that hurdle due to the insufficiently robust data obtained in a recently closed clinical trial. This review aims at discussing the reasons for hybridoma-derived idiotype vaccines, more difficult to produce but also more successful than recombinant idiotype vaccines so far, are unlikely to gain regulatory approval. In particular, it is necessary to examine the many peculiar features of this therapeutic approach in a broader context, with special attention to concepts like customized active immunotherapy and randomization. Most published trials based on hybridoma-derived idiotype vaccines are being analyzed, together with the yet non-peer reviewed data from the only randomized study conducted so far with this product, and with the main trials on recombinant idiotype vaccines for thorough comparison. All in all, the sole randomized trial ever conducted on hybridoma-derived idiotype vaccines failed to achieve its primary clinical end point because of an insufficient accrual and because the statistical significance achieved was not as stringent as required for regulatory approval.
Collapse
|
6
|
Abstract
The clonal immunoglobulin idiotype displayed on the surface of most malignant B cells is a patient- and tumour-specific antigen that can be used for therapeutic vaccination. Several studies have confirmed the biological efficacy of soluble protein idiotypic vaccination and two clinical trials have shown the clinical efficacy of this procedure. One study has demonstrated clinical benefit associated with idiotypic vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to the vaccine. While scepticism towards this type of non-toxic medical intervention is mounting, such patient-specific treatments might yet see the light of day through better designed clinical trials.
Collapse
Affiliation(s)
- Maurizio Bendandi
- Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.
| |
Collapse
|
7
|
Passoni L, Gambacorti-Passerini C. ALK a Novel Lymphoma-associated Tumor Antigen for Vaccination Strategies. Leuk Lymphoma 2009; 44:1675-81. [PMID: 14692518 DOI: 10.1080/1042819031000099625] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The discovery of Tumor Associated Antigens (TAAs) demonstrated that tumor cells can be specifically recognized by the immune system raising the hypothesis that tumors express antigens that Cytotoxic T Lymphocytes (CTLs) can potentially attack. The identification of immunogenic epitopes led to their use as targets to mediate the specific clearance of neoplastic cells by TAA targeting strategies such as vaccination strategies. One of the critical issues in the development of efficient vaccination protocols is the identification of the appropriate TAAs. The TAA should be effective as a "tumor rejection antigen" able to induce an immune response that will affect tumor growth. A distinct pathologic entity characterized by the expression of the Anaplastic Lymphoma Kinase (ALK) protein and named "ALKoma" has recently emerged within the heterogeneous group of CD30+ Anaplastic Large Cell Lymphoma (ALCL). ALK is a receptor tyrosine kinase whose expression is normally restricted to a few scattered cells in the nervous system. Its pathological expression in lymphoma cells is due to a chromosomal translocation that leads to the formation of an ALK-derived oncogenic fusion proteins. ALK fusion proteins ectopically over-expressed and constitutively activated in lymphoid cells play a key role in the neoplastic transformation by the aberrant phosphorylation of intracellular substrates that likely contributes to the molecular pathogenesis of ALCL. The high level of ALK expression in lymphoma cells and its direct role in lymphomagenesis, combined with the fact that normal ALK is expressed at low levels in the immune privileged nervous system, makes ALK an ideal lymphoma-specific target for immunotherapy of ALK+ALCL.
Collapse
Affiliation(s)
- Lorena Passoni
- Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
| | | |
Collapse
|
8
|
Sinha R, Shenoy PJ, Flowers CR. Idiotype vaccine strategies for improving outcomes in follicular lymphoma. Expert Opin Biol Ther 2008; 8:1213-23. [PMID: 18613772 DOI: 10.1517/14712598.8.8.1213] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Follicular lymphoma (FL) is a common indolent lymphoma associated with a relapsing course. Preclinical models and clinical studies demonstrate that immunizing FL patients against their own tumor idiotype induces humoral and cellular immunity and supresses tumor growth. METHODS We review idiotype vaccine strategies that have been tested in FL patients in frontline and relapsed settings to examine the safety and efficacy of this approach. RESULTS Several Phase II trials of recombinant or hybridoma-produced vaccines or vaccines combined with other immunotherapy demonstrate cellular and humoral anti-idiotype responses and clinical responses, indicating that idiotype vaccines provide promise for improving FL outcomes. CONCLUSION These strategies are now being evaluated in Phase III trials but have yet to demonstrate clear advantages in progression-free survival.
Collapse
|
9
|
Abstract
Although advanced-stage follicular lymphoma (FL) has been considered incurable with standard therapy, novel strategies that utilize immunotherapy provide opportunities for prolonging disease-free survival. While passive immunotherapy with antibodies targeting the CD20 antigen on B cells has been the most widely applied lymphoma immunotherapy, active immunization with vaccines derived from the immunoglobulin idiotype present on the surface of FL provides an opportunity to induce specific humoral and cellular immune responses to the tumor, and have been demonstrated to produce significant benefits in prolonging disease-free survival. Promoting the benefits of all forms of immunotherapy will likely depend upon improving complete remission rates with initial treatment. BiovaxID, a patient-specific idiotype vaccine, has demonstrated durable remissions when administered to FL patients in first complete remission along with keyhole limpet hemocyanin and granulocyte-macrophage colony-stimulating factor, and is now undergoing evaluation in a pivotal Phase III clinical trial.
Collapse
Affiliation(s)
- Christopher R Flowers
- Lymphoma Clinic, Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute, 1365 Clifton Road, N.E. Building C, Suite 3006, Emory University, Atlanta, GA 30322, USA.
| |
Collapse
|
10
|
Degan M, Rupolo M, Bo MD, Stefanon A, Bomben R, Zucchetto A, Canton E, Berretta M, Nanni P, Steffan A, Ballerini PF, Damiani D, Pucillo C, Attadia V, Colombatti A, Gattei V. Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia. ACTA ACUST UNITED AC 2004; 5:123-6. [PMID: 15453928 DOI: 10.3816/clm.2004.n.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Mutational status of immunoglobulin heavy-chain variable-region (IgVH) genes, along with CD38 expression, is a prognostic marker in B-cell chronic lymphocytic leukemia (B-CLL). Configuration of IgVH genes displaying > 2% mismatch has been shown to correlate with longer survivals. In a series of 64 B-CLLs, we failed to confirm the prognostic value of the IgVH gene mutational status by using the suggested cutoff. However, the IgVH mutational status maintained its prognostic value only when evidence of antigen-driven selection could be documented. This was accomplished by applying statistical methods aimed at evaluating a significant skewing of replacement mutations from framework to complementary determining regions, as it occurs during germinal center differentiation of B cells. These data caution against wide application of the 2% somatic mutation cutoff as a prognostic determinant without demonstration of antigen-driven selection.
Collapse
Affiliation(s)
- Massimo Degan
- Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Therapeutic cancer vaccines treat disease by stimulating the body's immune system. They are a form of active immunotherapy with the goal of producing an immune response that involves the cellular and humoral components of the immune system. These two components appear to be complementary and work together to induce tumor regression and long-lasting immunity to the disease being treated. This article reviews the history of cancer vaccine development, autologous and allogeneic vaccines, vaccine targets, carrier proteins, adjuvants, and clinical trial data of studies evaluating cancer vaccines. Knowledge of this emerging cancer treatment option will enable oncology nurses to be informed about cancer vaccines and accurately provide information about them to patients.
Collapse
|
12
|
Zhang M, Dong Z, Li J, Zhao G, Chen C, Li A. Humoral immunoreaction induced by TCR DNA vaccine for β chain of T cell lymphoma. Vaccine 2004; 22:2031-41. [PMID: 15121317 DOI: 10.1016/j.vaccine.2003.05.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2002] [Revised: 01/14/2003] [Accepted: 05/13/2003] [Indexed: 11/16/2022]
Abstract
We exploited the humoral immunoreaction of mice induced by TCR DNA vaccine of beta chain of T cell lymphoma. The plasmids of pcDNA3.1/TCR V beta 8 was constructed. The BALB/c mice were randomly divided into four groups which were pcDNA3.1, pcDNA3.1/TCR V beta 8, pcDNA3.1/TCR V beta 8 + CpG + liposome and phosphorothioate CpG groups with six mice in each group. Vaccines were injected in bilateral musculus quadriceps femoris of mice in the 0, second, and fourth week, respectively. The antibody formation was tested by indirect immuofluorescence in the 0, second, fourth, sixth and eighth weeks, respectively, before and after immunization. Production of antibody against TCR V beta 8 antigen was observed in the groups of pcDNA3.1/TCR V beta 8 and pcDNA3.1/TCR V beta 8 + CpG + liposome. The antibody titer began to rise in the fourth week and attain the maximal value in the sixth week. The antibody titer in the group of pcDNA3.1/TCR V beta 8 + CpG + liposome was higher than that in the group of pcDNA3.1/TCR V beta 8 in the fourth and eighth weeks (both P<0.01); the antibody titer in the group of pcDNA3.1/TCR V beta 8 + CpG + liposome was markedly higher than that in the group of pcDNA3.1/TCR V beta 8 in the sixth week (P<0.001). The result indicate that TCR V beta 8 antigen can induce formation of special antibody in mice. CpG and liposome can improve the humoral immunoreaction induced by TCR V beta 8 gene vaccine.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibody Formation/immunology
- Antibody Specificity
- Base Sequence
- Biolistics
- CpG Islands
- DNA, Complementary/biosynthesis
- DNA, Complementary/genetics
- Endonucleases/immunology
- Fluorescent Antibody Technique
- Humans
- Jurkat Cells
- Lymphoma, T-Cell/immunology
- Male
- Mice
- Mice, Inbred BALB C
- Molecular Sequence Data
- Plasmids/genetics
- Plasmids/immunology
- RNA/analysis
- RNA/biosynthesis
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/immunology
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription, Genetic
- Vaccines, DNA/immunology
Collapse
Affiliation(s)
- Mingzhi Zhang
- Tumor Department, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
| | | | | | | | | | | |
Collapse
|
13
|
Pession A, Tonelli R, Canderan G, Bendandi M, Rosolen A, Basso K, Basso G, Locatelli F, Zabalegui N, Paolucci G. Non-radiolabelled PCR consensus primers and automatic sequencing enable rapid identification of tumor-specific V(H) CDR3 in aggressive B-cell malignancies. Leuk Lymphoma 2004; 44:1597-601. [PMID: 14565664 DOI: 10.3109/10428190309178784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Even though the results of current therapy are improved for B-cell acute lymphoblastic leukemia (B-ALL) and Burkitt's lymphoma (BL), prognosis of relapsed mature B-ALL and BL still remain extremely poor. In this study, we investigated the possibility of applying the use of non-radiolabelled PCR consensus primers and automatic sequencing for the rapid identification of the tumor-specific V(H) CDR3 nucleotide sequence, in mature B-ALL and BL. RNA was extracted from four consecutive, unselected samples from BL cases and three consecutive, unselected samples from mature B-ALL cases. The feasibility of the identification of the tumor-specific V(H) CDR3 nucleotide sequence was then assessed by using non-radiolabelled PCR consensus primers with automatic sequencing. The tumor-specific V(H) CDR3 nucleotide sequence was successfully identified for all seven patients (3 mature B-ALL and BL). The time required was substantially lower than that of the other methods previously published, despite the poor quality of some of the samples. The procedure showed rapidity, reliability and reproducibility. The characteristics of the methodology applied widen the possibility of developing anti-idiotypic therapeutic strategies, even in these B-cell malignancies.
Collapse
Affiliation(s)
- Andrea Pession
- Department of Pediatrics, University of Bologna, Ospedale S. Orsola, Via Massarenti 11, 40100 Bologna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
|
15
|
N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11:795-798. [DOI: 10.11569/wcjd.v11.i6.795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
16
|
Abken H, Hombach A, Reinhard G, Märten A, Schlimper C, Glasmacher A, Bieber T, Schmidt-Wolf IGH. Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences. Leuk Lymphoma 2003; 44:583-92. [PMID: 12769334 DOI: 10.1080/1042819021000055318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Recurrence of disease after autologous hematopoietic stem cell transplantation is at least partly due to contamination of the reinfused transplant with tumor cells, thereby limiting the clinical outcome after transplantation. On the other hand, immunological effector cells are capable of purging bone marrow transplants in vitro and of destroying disseminated tumor cells in vivo. Cellular immunotherapy subsequent to autologous stem cell transplantation is therefore expected to have a major impact on recurrence rates of the disease. In this review, we present various strategies utilizing immunologic effector cells for elimination of disseminated tumor cells and discuss the advantages and limitations of cellular immunotherapy after autologous hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- Hinrich Abken
- Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany
| | | | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Jenner MJ, Summers KE, Norton AJ, Amess JA, Arch RS, Young BD, Lister TA, Fitzgibbon J, Goff LK. JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements. Br J Haematol 2002; 118:550-8. [PMID: 12139744 DOI: 10.1046/j.1365-2141.2002.03623.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Follicular lymphoma (FL) characteristically bears the t(14;18)(q32;q21). However, only approximately 75% of the consequent Bcl-2 breakpoints lie within the major breakpoint region (MBR) or the minor cluster region (mcr). While these can be quantified by cluster region-specific real-time quantitative polymerase chain reaction (RQ-PCR), a significant proportion of cases are left requiring a customized approach. Therefore, an RQ-PCR assay for the quantification of Bcl-2/IgH breakpoints has been developed that uses germline JH TaqMan probes and germline JH primers in combination with customized forward primers. Validation of this approach by comparison with an established MBR RQ-PCR showed both techniques to be concordant across a wide range of copy numbers with a sensitivity of five copies per 10(5) cells. In addition, to generate standard curves equating to diverse Bcl-2/IgH rearrangements, a strategy for using placental DNA as a surrogate standard was devised. The performance of the assay in detecting molecular evidence of disease in sequential biopsies from five patients (three with atypical Bcl-2/IgH breakpoints identified by long-range or inverse PCR, one MBR+ and one mcr+) was tested. This alternative approach represents a sensitive and specific means of quantifying common and atypical Bcl-2/IgH rearrangements and maximizes the number of patients with FL suitable for molecular monitoring.
Collapse
Affiliation(s)
- Michael J Jenner
- CRUK Medical Oncology Unit, Department of Histopathology, St. Bartholomew's Hospital, West Smithfield, London EC1A 6BE, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Leis JF, Maziarz RT. Specific Immunotherapy for Non-Hodgkin's Lymphoma. Lab Med 2001. [DOI: 10.1309/1mwt-476a-fa6m-75ru] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- Jose F. Leis
- Division of Hematology and Medical Oncology, Adult Bone Marrow Transplant Program, Oregon Health & Sciences University, Portland, OR, 97201
| | - Richard T. Maziarz
- Division of Hematology and Medical Oncology, Adult Bone Marrow Transplant Program, Oregon Health & Sciences University, Portland, OR, 97201
| |
Collapse
|
20
|
Bendandi M, Tonelli R, Maffei R, Botti S, Turi C, Sartini R, Inogés S, Calvillo MR, Zinzani PL, Pession A, Pileri SA, Paolucci G. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann Oncol 2001; 12:1479-84. [PMID: 11762822 DOI: 10.1023/a:1012586905273] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning. PATIENTS AND METHODS In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific VH CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures. RESULTS The tumor-specific VH CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific VH CDR3 was also found in at least 8 of 10 of them. CONCLUSIONS The proposed method allows the ability to quickly identify the B-cell tumor-specific VH CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.
Collapse
Affiliation(s)
- M Bendandi
- Clínica Universitaria, Department of Hematology, University of Navarra, Pamplona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Lionberger JM, Armitage JO. Advances in the management of patients with non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2001; 1:43-52. [PMID: 12113132 DOI: 10.1586/14737140.1.1.43] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4% per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.
Collapse
Affiliation(s)
- J M Lionberger
- University of Nebraska Medical Center, 986545 Nebraska Medical Center, Omaha, NE 68198-6545, USA
| | | |
Collapse
|
22
|
Recent publications in hematological oncology. Hematol Oncol 2001. [PMID: 11276044 DOI: 10.1002/hon.671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|